サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1722140

初代肝細胞市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2025年～2032年）- 製品別、種別、用途/アッセイ別、エンドユーザー別、地域別、企業別）

Primary Hepatocytes Market - Global Primary Hepatocytes Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product, By Species, By Application/Assay, By End User, By Geographic Coverage and By Company)

出版日
ページ情報
英文 180 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.33円
初代肝細胞市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2025年～2032年）- 製品別、種別、用途/アッセイ別、エンドユーザー別、地域別、企業別）
出版日: 2025年05月08日
発行: Fairfield Market Research
ページ情報: 英文 180 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の初代肝細胞の市場規模は今後数年間で大幅な成長を遂げ、2032年には4億690万米ドルに達すると予測されています。これは2025年の2億6,360万米ドルから大幅に増加したことを意味し、2025年から2032年までの予測期間中の複合年間成長率（CAGR）6.4％を反映しています。この急成長の主な要因は、肝臓関連疾患の有病率が上昇していることと、医薬品開発や毒性試験において、より予測性の高いin vitroモデルに対する需要が高まっていることです。

市場の洞察

初代肝細胞は、肝疾患研究、前臨床薬物試験、毒性学的評価の要となっています。肝機能を正確に模倣できることから、薬物代謝、酵素活性、肝毒性を調べるのに理想的です。スフェロイドや共培養技術などの3D培養システムの最近の進歩は、in vivoの肝臓微小環境をより忠実にシミュレートすることを可能にし、肝細胞ベースのアッセイの関連性を高めています。

研究者や製薬会社は、機能的な完全性を維持しながら供給量の制限を克服するために、幹細胞由来の肝細胞を利用するようになってきています。この動向は、倫理的な研究慣行への関心の高まりや動物実験削減の規制圧力と相まって、肝細胞ベースのin vitroシステムの普及を後押ししています。

市場促進要因

市場促進要因のひとつは、非アルコール性脂肪性肝疾患（NAFLD）や肝炎を含む肝疾患の増加です。これらの疾患は、創薬や治療試験を効果的にサポートできる信頼性の高いin vitroモデルに対する需要を生み出しています。ヒト肝細胞に近い初代肝細胞は、この点で不可欠なツールです。

市場成長を促進するもう一つの主な要因は、世界のがん罹患率の上昇です。世界保健機関（WHO）は、2040年までにがん患者が47％増加すると予測しており、より効果的な薬剤スクリーニング法の緊急の必要性を強調しています。3D肝細胞モデルは、薬物の毒性と有効性の評価において、より高い予測力を提供し、腫瘍学研究において非常に貴重な存在となっています。LonzaやThermo Fisher Scientificなどの主要企業は、この需要に応えるため、臓器オンチップや3D肝細胞モデルに積極的に投資しています。

さらに、FDAやEMAなどの規制機関は、早期段階の医薬品スクリーニングを改善し、動物実験を減らすために、ヒトに関連するin vitroモデルの使用を強調しています。このような規制当局の支援は、最新の医薬品開発における初代肝細胞の役割をさらに強固なものにしています。

ビジネスの機会

この市場は、特に3D細胞培養技術への関心の高まりを受けて、ビジネスの機会に溢れています。これらのシステムは複雑な組織構造を再現し、腫瘍の成長、転移、薬剤耐性などの生物学的プロセスについてより正確な洞察を提供します。患者由来の細胞から作製されたオルガノイドは、個別化医療への応用に道を開いています。

さらに、動物実験規制の厳格化により、肝細胞ベースのモデルに新たな道が開かれつつあります。企業は、前臨床研究の信頼性を高めつつ、進化する倫理基準に沿った革新的なスクリーニングツールを開発することで、このシフトを活用しています。スケーラブルで費用対効果の高いソリューションの需要は、新興企業や新興プレーヤーに技術革新と事業拡大の機会をもたらしています。

地域分析

北米は、世界の原発性肝細胞市場において依然として支配的な地域です。高度なヘルスケアインフラ、研究開発への多額の投資、製薬企業やバイオテクノロジー企業の強力なプレゼンスが主要な地位を占めています。肝疾患の発生率が高く、革新的な医薬品開発を支援する規制環境も需要を後押ししています。

欧州も、確立された医薬品セクターと先進的な規制政策に後押しされ、力強い成長を遂げている主要地域のひとつです。ドイツ、フランス、英国などの諸国は、医薬品開発パイプラインに試験管内システムを組み込む取り組みを主導しています。欧州医薬品庁（EMA）は、動物実験に代わる試験法の推進を続けており、初代肝細胞の採用拡大を後押ししています。

主要参入企業

競合情勢は、業界大手各社の戦略的投資、製品イノベーション、提携によって特徴付けられます。各社は、進化する市場の需要に対応するため、細胞分離技術、凍結保存技術、アッセイ適合性の向上に注力しています。

最近の業界動向

2024年3月、Merckは上海のM Lab（TM）Collaboration Centerに1,400万米ドルを投資し、バイオ医薬品研究をサポートするための新しい生物学的アプリケーションとトレーニングラボの提供を拡大しました。

2024年2月、ブラジルのサンパウロに2,000万米ドルの物流センターを開設し、ラテンアメリカのライフサイエンス分野の顧客へのサービス効率を向上させます。

2023年2月、ATCCは米国薬局方（USP）と長期パートナーシップを締結し、生物学的製剤の標準物質と標準を共同開発し、品質とコンプライアンスを強化します。

市場セグメンテーション

製品別

  • 凍結保存懸濁肝細胞
  • 新鮮懸濁肝細胞
  • 3D（スフェロイド）肝細胞
  • 拡張肝細胞（プレート可能）
  • 非特異化肝細胞

種別

  • ヒト
  • ラット
  • マウス
  • 犬
  • サル
  • 馬
  • その他

用途別/アッセイ別

  • 細胞生存率アッセイ
  • シトクロム酵素活性
  • 高含量細胞毒性
  • トランスポーター阻害アッセイ
  • インビトロ内在性クリアランス
  • リン脂質アッセイ
  • その他

エンドユーザー別

  • バイオ製薬会社
  • 学術研究機関
  • 受託研究機関

地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

当レポートでは、世界の初代肝細胞市場について調査し、市場の概要とともに、製品別、種別、用途/アッセイ別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • 経済概要
  • PESTLE分析
  • 初代肝細胞市場、製品の採用
  • 地域別の規制シナリオ
  • バリューチェーン分析

第3章 世界の初代肝細胞市場の見通し、2019年～2032年

  • 世界の初代肝細胞市場の見通し：製品別、金額（100万米ドル）、2019年～2032年
  • 世界の初代肝細胞市場の見通し：種別、金額（100万米ドル）、2019年～2032年
  • 世界の初代肝細胞市場の見通し：用途別/アッセイ別、金額（100万米ドル）、2019-2032年
  • 世界の初代肝細胞市場の見通し：エンドユーザー別、金額（100万米ドル）、2019年～2032年
  • 世界の初代肝細胞市場の見通し：地域別、金額（100万米ドル）、2019年～2032年

第4章 北米の初代肝細胞市場の見通し、2019年～2032年

第5章 欧州の初代肝細胞市場の見通し、2019年～2032年

第6章 アジア太平洋の初代肝細胞市場の見通し、2019年～2032年

第7章 ラテンアメリカの初代肝細胞市場の見通し、2019年～2032年

第8章 中東・アフリカの初代肝細胞市場の見通し、2019年～2032年

第9章 競合情勢

  • 2025年の企業市場シェア分析
  • 競合ダッシュボード
  • 企業プロファイル
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Lonza
    • Takara Bio Inc.
    • American Type Culture Collection (ATCC)
    • Corning Inc.
    • Cell Biologics, Inc.
    • Creative Bioarray
    • Axol Bioscience Ltd.
    • HiMedia Laboratories
    • NEXEL Co., Ltd.
    • AnaBios
    • Cytes Biotechnologies S.L.
    • ZenBio, Inc. (BioIVT)
    • iXCells Biotechnologies
    • ScienCell Research Laboratories, Inc.
    • Kerafast
    • Kosheeka
    • XenoTech
    • LifeNet Health LifeSciences
    • Cell Guidance Systems LLC
    • Applied Biological Materials Inc. (abm)
    • Discovery Life Sciences
    • Innoprot
    • Novabiosis

第10章 付録

目次

The global primary hepatocytes market is poised for substantial growth over the coming years, reaching an estimated valuation of US$ 406.9 million by 2032. This marks a significant increase from the US$ 263.6 million recorded in 2025, reflecting a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2025 to 2032. The surge is largely attributed to the escalating prevalence of liver-related diseases and the increasing demand for more predictive in vitro models in drug development and toxicology testing.

Market Insights

Primary hepatocytes have become a cornerstone in liver disease research, preclinical drug testing, and toxicological assessments. Their ability to accurately mimic liver function makes them ideal for investigating drug metabolism, enzyme activity, and hepatotoxicity. Recent advancements in 3D culture systems, such as spheroids and co-culture technologies, are elevating the relevance of hepatocyte-based assays by enabling closer simulation of the in vivo liver microenvironment.

Researchers and pharmaceutical companies are increasingly turning to stem cell-derived hepatocytes to overcome supply limitations while maintaining functional integrity. This trend, coupled with a growing focus on ethical research practices and regulatory pressure to reduce animal testing, is driving the widespread adoption of hepatocyte-based in vitro systems.

Market Drivers

One of the key drivers of the market is the increasing incidence of liver diseases, including Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatitis. These conditions are generating demand for reliable in vitro models that can effectively support drug discovery and therapeutic testing. Primary hepatocytes, which offer a close representation of human liver cells, are essential tools in this regard.

Another major factor fueling market growth is the global rise in cancer prevalence. The World Health Organization (WHO) anticipates a 47% increase in cancer cases by 2040, which underscores the urgent need for more effective drug screening methods. 3D hepatocyte models are proving invaluable in oncology research, offering greater predictive power in assessing drug toxicity and efficacy. Leading companies such as Lonza and Thermo Fisher Scientific are actively investing in organ-on-a-chip and 3D liver models to meet this demand.

Additionally, regulatory bodies like the FDA and EMA are emphasizing the use of human-relevant in vitro models to improve early-stage drug screening and reduce animal testing. This regulatory support is further solidifying the role of primary hepatocytes in modern drug development.

Business Opportunities

The market is brimming with opportunities, especially in the wake of growing interest in 3D cell culture technologies. These systems replicate complex tissue architecture, offering more accurate insights into biological processes such as tumor growth, metastasis, and drug resistance. Organoids created from patient-derived cells are paving the way for personalized medicine applications.

Moreover, stricter animal testing regulations are opening new avenues for hepatocyte-based models. Companies are capitalizing on this shift by developing innovative screening tools that align with evolving ethical standards while enhancing the reliability of preclinical studies. The demand for scalable, cost-effective solutions also presents opportunities for startups and emerging players to innovate and expand.

Regional Analysis

North America remains the dominant region in the global primary hepatocytes market. Its advanced healthcare infrastructure, substantial investment in R&D, and strong presence of pharmaceutical and biotechnology companies contribute to its leading position. The high incidence of liver disorders and a regulatory environment that supports innovative drug development practices are also driving demand.

Europe is another key region experiencing robust growth, fueled by its well-established pharmaceutical sector and progressive regulatory policies. Countries like Germany, France, and the United Kingdom are leading efforts in integrating in vitro systems into drug development pipelines. The European Medicines Agency (EMA) continues to promote alternatives to animal testing, thereby supporting increased adoption of primary hepatocytes.

Key Players

The competitive landscape is characterized by strategic investments, product innovations, and collaborations among major industry players. Companies are focusing on improving cell isolation techniques, cryopreservation technologies, and assay compatibility to meet the evolving demands of the market.

Prominent players in the primary hepatocytes market include:

  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza
  • Takara Bio Inc.
  • American Type Culture Collection (ATCC)
  • Corning Inc.
  • Cell Biologics, Inc.
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories
  • AnaBios
  • Cytes Biotechnologies S.L.
  • ZenBio, Inc. (BioIVT)
  • iXCells Biotechnologies
  • ScienCell Research Laboratories, Inc.
  • Kerafast
  • Kosheeka
  • XenoTech
  • LifeNet Health LifeSciences
  • Applied Biological Materials Inc. (abm)
  • Discovery Life Sciences
  • Innoprot
  • Novabiosis

Recent Industry Developments

In March 2024, Merck invested US$ 14 million in its M Lab(TM) Collaboration Center in Shanghai, expanding its offerings with new biological application and training labs to support biopharma research.

In February 2024, Merck opened a US$ 20 million distribution center in Sao Paulo, Brazil, aimed at improving service efficiency for its life science clients in Latin America.

In February 2023, ATCC entered a long-term partnership with the U.S. Pharmacopeia (USP) to co-develop reference materials and standards for biologic medicines, bolstering quality and compliance.

Market Segmentation

By Product:

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species:

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse
  • Others

By Application/Assay:

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay
  • Others

By End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Economic Overview
    • 2.6.1. World Economic Projections
  • 2.7. PESTLE Analysis
  • 2.8. Primary Hepatocytes Market, Product Adoption
  • 2.9. Regulatory Scenario by Region
  • 2.10. Value Chain Analysis

3. Global Primary Hepatocytes Market Outlook, 2019-2032

  • 3.1. Global Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cryopreserved Suspension Hepatocytes
      • 3.1.1.2. Fresh Suspension Hepatocytes
      • 3.1.1.3. 3D (Spheroid) Hepatocytes
      • 3.1.1.4. Expanded Hepatocytes (Plateable)
      • 3.1.1.5. Non-characterized Hepatocytes
  • 3.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Human
      • 3.2.1.2. Rat
      • 3.2.1.3. Mouse
      • 3.2.1.4. Dog
      • 3.2.1.5. Monkey
      • 3.2.1.6. Horse
      • 3.2.1.7. Others
  • 3.3. Global Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cell Viability Assay
      • 3.3.1.2. Cytochrome Enzyme Activity
      • 3.3.1.3. High Content Cytotoxicity
      • 3.3.1.4. Transporter Inhibition Assay
      • 3.3.1.5. In Vitro Intrinsic Clearance
      • 3.3.1.6. Phospholipids Assay
      • 3.3.1.7. Others
  • 3.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 3.4.1. Key Highlights
      • 3.4.1.1. Biopharmaceutical companies
      • 3.4.1.2. Academic and Research institutes
      • 3.4.1.3. Contract Research Organizations
  • 3.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Mn), 2019-2032
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. East Asia
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Primary Hepatocytes Market Outlook, 2019-2032

  • 4.1. North America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cryopreserved Suspension Hepatocytes
      • 4.1.1.2. Fresh Suspension Hepatocytes
      • 4.1.1.3. 3D (Spheroid) Hepatocytes
      • 4.1.1.4. Expanded Hepatocytes (Plateable)
      • 4.1.1.5. Non-characterized Hepatocytes
  • 4.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Human
      • 4.2.1.2. Rat
      • 4.2.1.3. Mouse
      • 4.2.1.4. Dog
      • 4.2.1.5. Monkey
      • 4.2.1.6. Horse
      • 4.2.1.7. Others
  • 4.3. North America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cell Viability Assay
      • 4.3.1.2. Cytochrome Enzyme Activity
      • 4.3.1.3. High Content Cytotoxicity
      • 4.3.1.4. Transporter Inhibition Assay
      • 4.3.1.5. In Vitro Intrinsic Clearance
      • 4.3.1.6. Phospholipids Assay
      • 4.3.1.7. Others
  • 4.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 4.4.1. Key Highlights
      • 4.4.1.1. Biopharmaceutical companies
      • 4.4.1.2. Academic and Research institutes
      • 4.4.1.3. Contract Research Organizations
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.2. U.S. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.3. U.S. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.4. U.S. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 4.5.1.5. Canada Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 4.5.1.6. Canada Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 4.5.1.7. Canada Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 4.5.1.8. Canada Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Primary Hepatocytes Market Outlook, 2019-2032

  • 5.1. Europe Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cryopreserved Suspension Hepatocytes
      • 5.1.1.2. Fresh Suspension Hepatocytes
      • 5.1.1.3. 3D (Spheroid) Hepatocytes
      • 5.1.1.4. Expanded Hepatocytes (Plateable)
      • 5.1.1.5. Non-characterized Hepatocytes
  • 5.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Human
      • 5.2.1.2. Rat
      • 5.2.1.3. Mouse
      • 5.2.1.4. Dog
      • 5.2.1.5. Monkey
      • 5.2.1.6. Horse
      • 5.2.1.7. Others
  • 5.3. Europe Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cell Viability Assay
      • 5.3.1.2. Cytochrome Enzyme Activity
      • 5.3.1.3. High Content Cytotoxicity
      • 5.3.1.4. Transporter Inhibition Assay
      • 5.3.1.5. In Vitro Intrinsic Clearance
      • 5.3.1.6. Phospholipids Assay
      • 5.3.1.7. Others
  • 5.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Biopharmaceutical companies
      • 5.4.1.2. Academic and Research institutes
      • 5.4.1.3. Contract Research Organizations
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.2. Germany Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.3. Germany Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.4. Germany Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.5. U.K. Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.6. U.K. Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.7. U.K. Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.8. U.K. Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.9. France Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.10. France Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.11. France Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.12. France Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.13. Spain Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.14. Spain Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.15. Spain Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.16. Spain Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.17. Italy Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.18. Italy Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.19. Italy Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.20. Italy Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.21. Russia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.22. Russia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.23. Russia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.24. Russia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 5.5.1.25. Rest of Europe Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 5.5.1.26. Rest of Europe Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 5.5.1.27. Rest of Europe Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 5.5.1.28. Rest of Europe Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia & Pacific Primary Hepatocytes Market Outlook, 2019-2032

  • 6.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cryopreserved Suspension Hepatocytes
      • 6.1.1.2. Fresh Suspension Hepatocytes
      • 6.1.1.3. 3D (Spheroid) Hepatocytes
      • 6.1.1.4. Expanded Hepatocytes (Plateable)
      • 6.1.1.5. Non-characterized Hepatocytes
  • 6.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Human
      • 6.2.1.2. Rat
      • 6.2.1.3. Mouse
      • 6.2.1.4. Dog
      • 6.2.1.5. Monkey
      • 6.2.1.6. Horse
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cell Viability Assay
      • 6.3.1.2. Cytochrome Enzyme Activity
      • 6.3.1.3. High Content Cytotoxicity
      • 6.3.1.4. Transporter Inhibition Assay
      • 6.3.1.5. In Vitro Intrinsic Clearance
      • 6.3.1.6. Phospholipids Assay
      • 6.3.1.7. Others
  • 6.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Biopharmaceutical companies
      • 6.4.1.2. Academic and Research institutes
      • 6.4.1.3. Contract Research Organizations
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia & Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.2. China Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.3. China Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.4. China Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.5. Japan Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.6. Japan Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.7. Japan Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.8. Japan Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.9. South Korea Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.10. South Korea Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.11. South Korea Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.12. South Korea Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.13. India Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.14. India Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.15. India Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.16. India Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.17. Southeast Asia Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.18. Southeast Asia Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.19. Southeast Asia Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.20. Southeast Asia Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 6.5.1.21. Rest of Asia Pacific Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 6.5.1.22. Rest of Asia Pacific Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 6.5.1.23. Rest of Asia Pacific Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 6.5.1.24. Rest of Asia Pacific Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Primary Hepatocytes Market Outlook, 2019-2032

  • 7.1. Latin America Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cryopreserved Suspension Hepatocytes
      • 7.1.1.2. Fresh Suspension Hepatocytes
      • 7.1.1.3. 3D (Spheroid) Hepatocytes
      • 7.1.1.4. Expanded Hepatocytes (Plateable)
      • 7.1.1.5. Non-characterized Hepatocytes
  • 7.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Human
      • 7.2.1.2. Rat
      • 7.2.1.3. Mouse
      • 7.2.1.4. Dog
      • 7.2.1.5. Monkey
      • 7.2.1.6. Horse
      • 7.2.1.7. Others
  • 7.3. Latin America Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cell Viability Assay
      • 7.3.1.2. Cytochrome Enzyme Activity
      • 7.3.1.3. High Content Cytotoxicity
      • 7.3.1.4. Transporter Inhibition Assay
      • 7.3.1.5. In Vitro Intrinsic Clearance
      • 7.3.1.6. Phospholipids Assay
      • 7.3.1.7. Others
  • 7.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Biopharmaceutical companies
      • 7.4.1.2. Academic and Research institutes
      • 7.4.1.3. Contract Research Organizations
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.2. Brazil Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.3. Brazil Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.4. Brazil Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.5. Mexico Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.6. Mexico Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.7. Mexico Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.8. Mexico Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 7.5.1.9. Rest of Latin America Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 7.5.1.10. Rest of Latin America Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 7.5.1.11. Rest of Latin America Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 7.5.1.12. Rest of Latin America Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Primary Hepatocytes Market Outlook, 2019-2032

  • 8.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product, Value (US$ Mn), 2019-2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cryopreserved Suspension Hepatocytes
      • 8.1.1.2. Fresh Suspension Hepatocytes
      • 8.1.1.3. 3D (Spheroid) Hepatocytes
      • 8.1.1.4. Expanded Hepatocytes (Plateable)
      • 8.1.1.5. Non-characterized Hepatocytes
  • 8.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Mn) and 2019-2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Human
      • 8.2.1.2. Rat
      • 8.2.1.3. Mouse
      • 8.2.1.4. Dog
      • 8.2.1.5. Monkey
      • 8.2.1.6. Horse
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Primary Hepatocytes Market Outlook, Application/Assay, Value (US$ Mn), 2019-2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cell Viability Assay
      • 8.3.1.2. Cytochrome Enzyme Activity
      • 8.3.1.3. High Content Cytotoxicity
      • 8.3.1.4. Transporter Inhibition Assay
      • 8.3.1.5. In Vitro Intrinsic Clearance
      • 8.3.1.6. Phospholipids Assay
      • 8.3.1.7. Others
  • 8.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Mn), 2019-2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Biopharmaceutical companies
      • 8.4.1.2. Academic and Research institutes
      • 8.4.1.3. Contract Research Organizations
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Mn), 2019-2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Countries Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.2. GCC Countries Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.3. GCC Countries Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.4. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.5. South Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.6. South Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.7. South Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.8. GCC Countries Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.9. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.10. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.11. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.12. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.13. Nigeria Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.14. Nigeria Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.15. Nigeria Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
      • 8.5.1.16. Nigeria Primary Hepatocytes Market by End User, Value (US$ Mn), 2019-2032
      • 8.5.1.17. Rest of Middle East & Africa Primary Hepatocytes Market by Product, Value (US$ Mn), 2019-2032
      • 8.5.1.18. Rest of Middle East & Africa Primary Hepatocytes Market by Species, Value (US$ Mn), 2019-2032
      • 8.5.1.19. Rest of Middle East & Africa Primary Hepatocytes Market by Application/Assay, Value (US$ Mn), 2019-2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Thermo Fisher Scientific Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. Lonza
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. Takara Bio Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. American Type Culture Collection (ATCC)
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Corning Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. Cell Biologics, Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Creative Bioarray
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Axol Bioscience Ltd.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. HiMedia Laboratories
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development
    • 9.3.11. NEXEL Co., Ltd.
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Product Portfolio
      • 9.3.11.3. Financial Overview
      • 9.3.11.4. Business Strategies and Development
    • 9.3.12. AnaBios
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Product Portfolio
      • 9.3.12.3. Financial Overview
      • 9.3.12.4. Business Strategies and Development
    • 9.3.13. Cytes Biotechnologies S.L.
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Product Portfolio
      • 9.3.13.3. Financial Overview
      • 9.3.13.4. Business Strategies and Development
    • 9.3.14. ZenBio, Inc. (BioIVT)
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Product Portfolio
      • 9.3.14.3. Financial Overview
      • 9.3.14.4. Business Strategies and Development
    • 9.3.15. iXCells Biotechnologies
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Product Portfolio
      • 9.3.15.3. Financial Overview
      • 9.3.15.4. Business Strategies and Development
    • 9.3.16. ScienCell Research Laboratories, Inc.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Product Portfolio
      • 9.3.16.3. Financial Overview
      • 9.3.16.4. Business Strategies and Development
    • 9.3.17. Kerafast
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Product Portfolio
      • 9.3.17.3. Financial Overview
      • 9.3.17.4. Business Strategies and Development
    • 9.3.18. Kosheeka
      • 9.3.18.1. Company Overview
      • 9.3.18.2. Product Portfolio
      • 9.3.18.3. Financial Overview
      • 9.3.18.4. Business Strategies and Development
    • 9.3.19. XenoTech
      • 9.3.19.1. Company Overview
      • 9.3.19.2. Product Portfolio
      • 9.3.19.3. Financial Overview
      • 9.3.19.4. Business Strategies and Development
    • 9.3.20. LifeNet Health LifeSciences
      • 9.3.20.1. Company Overview
      • 9.3.20.2. Product Portfolio
      • 9.3.20.3. Financial Overview
      • 9.3.20.4. Business Strategies and Development
    • 9.3.21. Cell Guidance Systems LLC
      • 9.3.21.1. Company Overview
      • 9.3.21.2. Product Portfolio
      • 9.3.21.3. Financial Overview
      • 9.3.21.4. Business Strategies and Development
    • 9.3.22. Applied Biological Materials Inc. (abm)
      • 9.3.22.1. Company Overview
      • 9.3.22.2. Product Portfolio
      • 9.3.22.3. Financial Overview
      • 9.3.22.4. Business Strategies and Development
    • 9.3.23. Discovery Life Sciences
      • 9.3.23.1. Company Overview
      • 9.3.23.2. Product Portfolio
      • 9.3.23.3. Financial Overview
      • 9.3.23.4. Business Strategies and Development
    • 9.3.24. Innoprot
      • 9.3.24.1. Company Overview
      • 9.3.24.2. Product Portfolio
      • 9.3.24.3. Financial Overview
      • 9.3.24.4. Business Strategies and Development
    • 9.3.25. Novabiosis
      • 9.3.25.1. Company Overview
      • 9.3.25.2. Product Portfolio
      • 9.3.25.3. Financial Overview
      • 9.3.25.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations